指南与共识其他结缔组织病

系统性硬化症临床试验联盟损伤指数(SCTC-DI)的研制与验证

Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
指南 / 共识 · Ann Rheum Dis · 2019-03-30

本研究旨在研制首个系统性硬化症(SSc)损伤指数(DI)。通过共识会议、系统文献回顾、331名专家问卷(>60%共识保留条目)、1568例澳大利亚队列的单变量分析(p<0.10保留)及多变量回归加权,最终形成23条目加权SCTC-DI,并在加拿大队列中外部验证,可预测发病率与死亡率。

要点

  • SCTC-DI为23条目加权工具,用于量化SSc器官损伤。
  • 研制结合专家共识(>60%共识)与数据驱动方法。
  • 外部验证显示SCTC-DI可预测发病率与死亡率。

核心结论

  • 通过共识与数据驱动方法相结合,研制出23条目加权SCTC-DI,并在外部队列中回顾性验证可预测发病率与死亡率。

研究设计与样本

  • 由SCTC工作组通过共识确定SSc损伤概念定义,结合系统文献回顾及患者伴侣与非风湿病专家咨询产生候选条目。
  • 邀请331名SCTC专家通过网页调查评分,保留>60%共识的条目;利用1568例澳大利亚前瞻性队列数据,保留与死亡和/或发病率终点单变量分析p<0.10的条目。
  • 采用多变量回归系数确定各条目加权评分,并在加拿大队列中进行外部验证。

主要发现

  • 58个条目中22个与死亡和/或发病率终点单变量关系有统计学意义,另1个条目因临床重要性由专家强制纳入多变量模型,最终形成23条目加权SCTC-DI。
  • SCTC-DI在外部队列中可预测发病率与死亡率。

关键数值与推荐

  • 专家共识阈值:条目需>60%共识方被保留。
  • 单变量筛选阈值:与死亡和/或发病率终点关联p<0.10的条目被保留。
  • 最终工具:23条目加权SCTC-DI。

临床怎么用

  • SCTC-DI可用于量化SSc患者器官损伤,并预测发病率与死亡率,辅助临床评估与随访。

局限性

  • 外部验证为回顾性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to develop the first Damage Index (DI) in systemic sclerosis (SSc). METHODS: The conceptual definition of 'damage' in SSc was determined through consensus by a working group of the Scleroderma Clinical Trials Consortium (SCTC). Systematic literature review and consultation with patient partners and non-rheumatologist experts produced a list of potential items for inclusion in the DI. These steps were used to reduce the items: (1) Expert members of the SCTC (n=331) were invited to rate the appropriateness of each item for inclusion, using a web-based survey. Items with >60% consensus were retained; (2) Using a prospectively acquired Australian cohort data set of 1568 patients, the univariable relationships between the remaining items and the endpoints of mortality and morbidity (Physical Component Summary score of the Short Form 36) were analysed, and items with p<0.10 were retained; (3) using multivariable regression analysis, coefficients were used to determine a weighted score for each item. The DI was externally validated in a Canadian cohort. RESULTS: Ninety-three (28.1%) complete survey responses were analysed; 58 of 83 items were retained. The univariable relationships with death and/or morbidity endpoints were statistically significant for 22 items, with one additional item forced into the multivariable model by experts due to clinical importance, to create a 23-item weighted SCTC DI (SCTC-DI). The SCTC-DI was predictive of morbidity and mortality in the external cohort. CONCLUSIONS: Through the combined use of consensus and data-driven methods, a 23-item SCTC-DI was developed and retrospectively validated.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Ferdowsi N, Huq M, Stevens W, et al. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. Ann Rheum Dis. 2019. PMID: 30928903. doi:10.1136/annrheumdis-2018-214764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。